Quantitative chemiluminescent immunoassay for NF-kappaB-DNA binding activity

Area of Science:

• Molecular Biology
• Immunology
• Biochemistry

Background:

• Nuclear factor-kappaB (NF-kappaB) is a key transcription factor regulating inflammatory and stress responses.
• Dysregulation of NF-kappaB is linked to various diseases, including cancer and atherosclerosis.
• The conventional Electrophoretic Mobility Shift Assay (EMSA) for NF-kappaB detection is slow and lacks quantification.

Purpose of the Study:

• To develop and validate a rapid, sensitive, and quantitative chemiluminescent immunoassay (QCI) for NF-kappaB DNA-binding activity.
• To compare the performance of the QCI with the established EMSA method.
• To assess the QCI's utility in analyzing NF-kappaB activity in diverse biological samples.

Main Methods:

• Development of a novel chemiluminescent immunoassay (QCI) for NF-kappaB DNA-binding.
• Validation using nuclear and cytosolic extracts from prostate cancer cells, rat liver, and human lymphocytes.
• Comparison of QCI results with the Electrophoretic Mobility Shift Assay (EMSA).

Main Results:

• The QCI provides results in 3-5 hours, significantly faster than EMSA.
• The QCI demonstrates high sensitivity (10pg NF-kappaB/well) and a wide quantitative linear range (10-1000pg NF-kappaB).
• The assay is adaptable for high-throughput analysis in a 96-well format and does not use radioactive isotopes.

Conclusions:

• The developed QCI is a superior alternative to EMSA for analyzing NF-kappaB DNA-binding activity.
• The QCI offers speed, sensitivity, quantification, safety, and high-throughput capabilities.
• This assay can measure both activated and total NF-kappaB, providing comprehensive insights into cellular signaling.